Hormone receptor status-Positive (ER and/or PR) Posts on Medivizor
Navigation Menu

Hormone receptor status-Positive (ER and/or PR) Posts on Medivizor

EndoPredict – can this prognostic test predict treatment success in breast cancer?

Posted by on May 30, 2019 in Breast cancer | 0 comments

In a nutshell This study investigated if a prognostic tool called EndoPredict can predict the success of treatment in hormone receptor-positive breast cancer (BC). They found that high scores using EndoPredict predicted treatment benefit in patients with BC.  Some background Breast cancer (BC) is one of the most common cancers. BC treatment...

Read More

Denosumab treatment in HR+ breast cancer

Posted by on Apr 30, 2019 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if adding the medication denosumab (Prolia, Xgeva) to cancer treatment for women with breast cancer reduces the risk of bone fractures. The study found that the patients treated with denosumab survived better, but there was no significant difference in the number of bone fractures. Some background Breast...

Read More

Risk of blood clots in breast cancer patients treated with aromatase inhibitors or tamoxifen

Posted by on Feb 20, 2019 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if the risk of patients with breast cancer developing a blood clot was higher if they were treated with aromatase inhibitors, or tamoxifen (Nolvadex). The study found that the patients treated with tamoxifen had a higher risk of developing blood clots compared to those treated with aromatase...

Read More

Joint pain and falls among women with breast cancer on aromatase inhibitors.

Posted by on Jan 18, 2019 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if joint pain is associated with falling down in patients with breast cancer who were treated with aromatase inhibitors. The study found that the patients who reported having joint pain were more likely to have a fall than those who had no joint pain. Some background Aromatase inhibitors are medications...

Read More

Joint pain management in obese breast cancer patients treated with aromatase inhibitors

Posted by on Dec 8, 2018 in Breast cancer | 0 comments

In a nutshell This article investigated the safety and effectiveness of adding Omega-3 fatty acid (O3-FA) to the management of joint pain in patients with breast cancer treated with aromatase inhibitors. The authors concluded that the addition of O3-FA is safe and gave the greatest benefit to patients who were obese.  Some background...

Read More

Palbociclib and Fulvestrant in Advanced Breast Cancer.

Posted by on Nov 3, 2018 in Breast cancer | 0 comments

In a nutshell This study investigated the overall survival rates of people with breast cancer who were treated with either palbociclib (Ibrance) plus fulvestrant (Faslodex), or just fulvestrant. The study found that the patients who received both palbociclib and fulvestrant had a longer overall survival compared to the group who only received...

Read More

10 years of treatment vs 5 years of treatment with hormone therapy in patients with early stage breast cancer.

Posted by on Oct 22, 2018 in Breast cancer | 0 comments

In a nutshell This study wanted to find out if continuing hormone therapy for 10 years was more effective than doing it for 5 years in patients with early stage breast cancer. The study found that the patients who continued treatment for 10 years survived for longer without the disease coming back compared to those who were only treated for 5...

Read More

Looking for patients with HER2 negative HR positive advanced breast cancer to test tesetaxel

Posted by on Aug 31, 2018 in Breast cancer | 0 comments

In a nutshell This trial is examining the effectiveness of tesetaxel plus a reduced dose of capecitabine for hormone receptor (HR) positive/HER2 negative advanced breast cancer. The main outcome to be measured will be progression free survival (time from treatment until disease progression). The details Breast cancer is classified into...

Read More